Prognostic and predictive value of a microRNA signature in stage II colon cancer: A microRNA expression analysis

The Lancet Oncology

Volumn 14, Issue 13, 2013, Pages 1295-1306

  Zhang, Jia Xing ^a   Song, Wu ^a   Chen, Zhen Hua ^a   Wei, Jin Huan ^a   Liao, Yi Ji ^b   Lei, Jian ^c   Hu, Ming ^c   Chen, Geng Zhen ^d   Liao, Bing ^a   Lu, Jian ^a   Zhao, Hong Wei ^a   Chen, Wei ^a   He, Yu Long ^a   Wang, Hui Yun ^b   Xie, Dan ^b   Luo, Jun Hang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MICRORNA; MICRORNA 103A 3P; MICRORNA 106B 5P; MICRORNA 143; MICRORNA 143 5P; MICRORNA 20A; MICRORNA 20A 5P; MICRORNA 21; MICRORNA 21 5P; MICRORNA 215; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLASSIFIER; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA GENE; STATISTICAL MODEL; SURVIVAL TIME;

AGED; CHEMOTHERAPY, ADJUVANT; CHINA; COLONIC NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888135550     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70491-1     Document Type: Article

References (38)

1. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A AJCC cancer staging manual 2010, Springer, New York, NY. 7th edn.
2. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011, 29:3381-3388.
3. Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029. Quasar Collaborative Group.
4. Morris EJ, Maughan NJ, Forman D, Quirke P Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut 2007, 56:1419-1425.
5. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
6. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 2011, 29:4620-4626.
7. Gangadhar T, Schilsky RL Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol 2010, 7:318-325.
8. Tejpar S, Bertagnolli M, Bosman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010, 15:390-404.
9. Wu WKK, Law PTY, Lee CW, et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2011, 32:247-253.
10. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
11. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008, 68:6416-6424.
12. Aslam MI, Taylor K, Pringle JH, Jameson JS MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 2009, 96:702-710.
13. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol 2013, 31:1775-1781.
14. Agesen TH, Sveen A, Merok MA, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012, 61:1560-1567.
15. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
16. Simon R, Altman DG Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994, 69:979-985.
17. Hair JFJ, Anderson RE, Tatham RL, Black WC Multivariate data analysis 1995, Prentice Hall, Saddle River, NJ. 4th edn.
18. Tibshirani R Regression shrinkage and selection via the lasso. J R Statist Soc B 1996, 58:267-288.
19. Tibshirani R The lasso method for variable selection in the Cox model. Stat Med 1997, 16:385-395.
20. Zhang HH, Lu WB Adaptive lasso for Cox's proportional hazards model. Biometrika 2007, 94:691-703.
21. Liu N, Chen NY, Cui RX, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 2012, 13:633-641.
22. Wei R, Huang GL, Zhang MY, et al. Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res 2013, 19:4780-4791.
23. Wang HY, Luo M, Tereshchenko IV, et al. A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genome Res 2005, 15:276-283.
24. Wang H, Ach RA, Curry B Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007, 13:151-159.
25. Camp RL, Dolled-Filhart M, Rimm DL X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10:7252-7259.
26. Heagerty PJ, Lumley T, Pepe MS Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56:337-344.
27. Bandres E, Cubedo E, Agirre X, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006, 5:29.
28. Motoyama K, Inoue H, Takatsuno Y, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009, 34:1069-1075.
29. Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 2010, 12:433-440.
30. Weissmann-Brenner A, Kushnir M, Yanai GL, et al. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Int J Oncol 2012, 40:2097-2103.
31. Farazi TA, Horlings HM, Ten Hoeve JJ, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 2011, 71:4443-4453.
32. Zhou X, Ren Y, Moore L, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 2010, 90:144-155.
33. Asangani IA, Rasheed SAK, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
34. Chen HY, Lin YM, Chung HC, et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 2012, 72:3631-3641.
35. Feng B, Dong TT, Wang LL, et al. Colorectal cancer migration and invasion initiated by microRNA-106a. PLoS One 2012, 7:e43452.
36. Qian X, Yu J, Yin Y, et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle 2013, 12:1385-1394.
37. Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 2012, 11:11-23.
38. Boni V, Bitarte N, Cristobal I, et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010, 9:2265-2275.